THE United Nations has cancelled all in-person meetings at its New York headquarters after five people in Niger’s U.N. mission were infected with the coronavirus, diplomats said.

After largely operating virtually since New York became a global COVID-19 hotspot in March, the 193-member world body had been holding some in-person gatherings again, with COVID-19 precautions such as requiring diplomats to wear masks, social distance and restricting the number of people at meetings.

In a letter to member states late on Monday, U.N. General Assembly President Volkan Bozkir said the U.N. medical unit had recommended cancelling in-person meetings on Tuesday, pending contact tracing with those infected.

Niger is a member of the 15-member Security Council, which last met in person on Thursday. Diplomats said people who attended Thursday’s meeting were being tested for COVID-19, and an in-person meeting on Syria planned for Tuesday was instead held virtually. – Thomson Reuters Foundation.

Source: The African Mirror

ON the 75th anniversary of the U.N.’s founding, experts warn human rights violations are flourishing and say the U.N. must adapt

CHRISTOPHER JOHNSON

DEFENDING human rights, a key mission of the United Nations, it seems, has never been harder.

A global pandemic has deepened inequality, pushed millions out of work and seen governments enforce restrictions on people’s movement and ramp up surveillance.

Oct 24 marks 75 years since the U.N. was founded in the aftermath of World War II.

The Thomson Reuters Foundation asked five former and current U.N. advisors how COVID-19 is impacting its the ability to protect human rights from New York to Nigeria.

VICTORIA TAULI-CORPUZ, FORMER U.N. SPECIAL RAPPORTEUR ON INDIGENOUS RIGHTS:

“Advocating for human rights issues entails visiting embassies to talk with diplomats and being present during the negotiations, which obviously cannot be done now.

Special Rapporteurs cannot go on country visits to monitor and report on human rights situations.

Virtual sessions have limited the capacities of human rights defenders to bring their issues to the sessions of the Human Rights Council.

The way some governments use authoritarian and military approaches in addressing the pandemic, instead of dealing with it as a public health issue, has resulted in human rights violations.

I believe that just like the rest of the world, the U.N. is still grappling with this new reality and they are still seeking appropriate ways of adapting to change.” 

DOMINIQUE DAY, CHAIR OF THE U.N. WORKING GROUP OF EXPERTS ON PEOPLE OF AFRICAN DESCENT: 

“From the very beginning, we saw an abandonment of human rights principles in the pandemic panic.

People of African descent have faced a higher risk of infection, severe illness, and mortality from the beginning, yet no special measures were taken by states, even as stark racial disparities emerged.

Coronavirus has been a global disaster, in part because some countries read ‘public health crisis’ to mean a break from human rights protection.

The U.N. has struggled to get the attention of the states and the powerbrokers that could have held the line on social protection, even as it has amplified the many human rights cases of abuse taking place during COVID-19.”

MICHAEL FAKHRI, LAW PROFESSOR AT THE UNIVERSITY OF OREGON AND U.N. SPECIAL RAPPORTEUR ON THE RIGHT TO FOOD:

“The coronavirus pandemic has shown that the U.N.’s commitment to Human Rights is inconsistent.

Instead of using Human Rights to solve the problems that exist today a lot of time is spent trying to explain why they are vital.

The U.N. is not internally reflecting about helping those in the system get through the pandemic.

If you don’t have access to the internet to attend virtual meetings for example you are unable to be in spaces to make your voice heard.”

MARY LAWLOR, U.N. SPECIAL RAPPORTEUR ON HUMAN RIGHTS DEFENDERS: 

“The virus has hit the work of human rights defenders hard but there is clearly a growing awareness across the world that societies need to be reorganised to cope with global challenges like the pandemic or the climate crisis.” 

SURYA DEVA, MEMBER OF THE U.N.’s WORKING GROUP ON BUSINESS AND HUMAN RIGHTS:

“The pandemic has hindered the ability of the U.N. to respond effectively to human rights issues.

Lack of funding for the U.N.’s various initiatives is a case in point.

But I think Covid-19 is an opportunity for the U.N. itself to build back better.

For example, it could institutionalize the use of technology in activities to cut down avoidable travel, to make meetings more inclusive and climate-friendly.”  – Thomson Reuters Foundation.

 

Source: The African Mirror

WHO foots the bill if people in poor countries fall sick with unexpected side-effects from coronavirus vaccines? It’s not clear and that’s a big problem in the battle to beat COVID-19.

The World Health Organization (WHO) has so far left the question of financial claims unresolved as it seeks to ensure shots are fairly distributed around the world, according to confidential documents reviewed by Reuters and six people familiar with discussions.

A similar situation emerged during the H1N1 swine flu pandemic in 2009-10. Back then, fears about potential compensation costs stymied the WHO’s efforts to get vaccines to low-income countries. Some health experts fear the U.N. body risks making the same mistake.

Under the WHO’s COVID-19 vaccine plans, known as COVAX, 92 poor countries are eligible to access vaccines at lower or no costs until the end of 2021, but liability conditions remain vague.

Without clearly stated terms, governments of poor states may be on the hook for potential compensation claims, which could put them off participating in the WHO-led scheme and risk prolonging the pandemic in places ill-equipped to cope, health experts say.

WHO and GAVI, a vaccine alliance which co-leads COVAX, said in a joint statement to Reuters that the scheme will try to solve liability and indemnification issues “while addressing the financial obligations this may impose on AMC-eligible economies,” referring to the group of 92 poorer states which includes most African and South-East Asian countries.

Vietnam, which is eligible for free or cheaper COVAX vaccines, is unlikely to use shots provided by the global facility, a Vietnamese health official told Reuters, saying supply deals it negotiated bilaterally with pharmaceutical companies were more transparent than COVAX’s terms.

Kenya, which is also eligible, said it was premature to say who should carry the liability for potential adverse effects but expected the vaccine makers to bear some of the responsibility, according to Rashid Aman, chief administrative secretary at the ministry of health.

Vastly underfunded — COVAX has received about a quarter of the $16 billion the WHO and GAVI say it needs by the end of next year — the scheme has left richer countries to fend for themselves when it comes to vaccine liability.

“Participants will be responsible for deployment and use of approved vaccines within their territories and assuming any liability associated with such use and deployment,” according to a COVAX document seen by Reuters detailing the terms for countries that must pay to join.

The group includes European Union nations, China and also middle-income states, such as Argentina, Iran, Iraq, South Africa and Mexico.

“The consequence of this arrangement is that these countries may end up being liable to pay a very high hidden price if something goes wrong,” a European Union senior official involved in talks with COVAX told Reuters.

This is one of the reasons why the EU has decided not to take delivery of vaccines through COVAX even though the 27-nation bloc has pledged money to the facility, the official said, noting that deals the EU is separately negotiating with vaccine companies involve clauses that make firms liable for potential compensation.

The United States has refused to fund COVAX and has instead sealed its own deals with drug companies, including offering a blanket legal immunity to COVID-19 vaccine makers in a bid to spur their investments in jabs.

China announced last week it would buy COVAX vaccines for 1% of its population.

A BARRIER FOR ACCESS?

There is no internationally approved COVID-19 vaccine, but the WHO estimates the first shot could be ready this year.

Adverse effects after a vaccine get regulatory approval are rare but the speed at which COVID-19 shots are being pursued increases the risks of unforeseen conditions – and of large litigation costs.

During the H1N1 flu pandemic, the WHO struggled to get vaccines to dozens of poor countries partly because it had agreed with pharmaceutical companies that poorer nations would be on the hook for compensation claims just like richer countries, the organisation acknowledged in a 2011 report.

“Some recipient countries felt WHO did not adequately explain that liability provisions included in the recipient agreement were the same as the liability provisions accepted by purchasing countries,” concluded the report of the WHO committee that reviewed the handling of the H1N1 flu pandemic.

Most of the estimated half-million people who died from H1N1 were in poorer countries.

COVID-19 has so far infected nearly 38 million people and killed at least a million.

There are nearly 200 coronavirus vaccines in development and many governments acknowledge that drugmakers are taking big financial risks in developing and manufacturing at an unprecedented speed — it usually takes 10-15 years to bring a vaccine to market — shots that may not be successful.

There is broad consensus that some of these costs should be covered by taxpayers and many rich countries already have public or private funds that could pay indemnities to victims.

But many poorer countries that have agreed to get vaccines through COVAX do not have such compensation schemes nor the financial resources to fund them.

This means that they could either face costs for which they have no insurance or that potential victims there might not be compensated at all.

“We are concerned how such arrangements could be a barrier for access to COVID-19 vaccines in lower and middle-income countries that cannot or do not want to take on liability for the vaccines,” Dimitri Eynikel of Doctors Without Borders, a medical non-governmental organisation, told Reuters.

The Gates Foundation, one of WHO’s largest funders, raised similar concerns in a meeting with health experts in September, a person who attended the meeting said.

“It is a high priority for the foundation that (..)distribution issues are resolved to ensure that decisions impacting delivery are as effective as possible,” a spokeswoman for the Gates Foundation told Reuters, adding that work was being done to address those issues.

In addition to potential compensation costs, the poorest countries that qualify for free or cheaper vaccines, are also required to chip in to buy vaccines with up to $2 billion by the end of 2021, a confidential GAVI document shows.

Those unable to pay could be exempted next year, but later on they “will be expected to co-finance COVID-19 vaccines with tiered contributions that reflect economies’ ability to pay,” according to the document, a copy of which was seen by Reuters.

Contributions from the poorest, which could be financed through loans and grants from international donors such as the World Bank, are expected to help plug the funding gap and achieve COVAX’s goal of buying at least 2 billion shots by the end of next year from a dozen vaccine makers. – Thomson Reuters Foundation.

Source: The African Mirror

"It will also provide financing and technical support so that developing countries can prepare for deploying vaccines at scale, in coordination with international partners."

World Bank approves $12 bln for Covid-19 vaccines

The World Bank has approved $12 billion for developing countries to finance the purchase and distribution of Covid-19 vaccines, tests and treatments. (Photo by AFP)

 

The World Bank said Tuesday that it approved $12 billion for developing countries to finance the purchase and distribution of Covid-19 vaccines, tests and treatment.

The financing "aims to support vaccination of up to a billion people," the bank said in a statement.

The money is part of an overall World Bank Group (WBG) package of up to $160 billion through June 2021 designed to help developing countries battle the novel coronavirus pandemic.

"This financing package helps signal to the research and pharmaceutical industry that citizens in developing countries also need access to safe and effective Covid-19 vaccines," the statement read. 

"It will also provide financing and technical support so that developing countries can prepare for deploying vaccines at scale, in coordination with international partners."

Access to safe and effective vaccines "and strengthened delivery systems is key to alter the course of the pandemic and help countries experiencing catastrophic economic and fiscal impacts move toward a resilient recovery," World Bank Group President David Malpass said in the statement.

 

The financing "will also support countries to access to Covid-19 tests and treatments, and expand immunization capacity to help health systems deploy the vaccines effectively," the statement added.

 

The financing approval was expected as Malpass had announced the project in late September.

While vaccines have yet to appear on the market, Malpass noted in an interview with the French daily Le Figaro that it was necessary to prepare because of the complicated vaccine distribution process.

The Bank's approach, according to the statement, draws on its "significant expertise in supporting large scale immunization programs for vaccine-preventable diseases, as well as public health programs to tackle infectious diseases such as HIV, tuberculosis, malaria and neglected tropical diseases."

Source: The NewVision